NCT06154967

To Explore the Effect of Immune-induced Stereotactic Body Radiotherapy (SBRT) on Reversing Immunoresistance in Stage IIIc/IV Non-small Cell Lung Cancer (NSCLC)

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to learn about in describe participant population. The main questions it aims to answer are: the outcomes of the efficacy (ORR) and safety (adverse events, including irAEs, AE, SAEs, and laboratory indicators) of continued immunotherapy in patients with immune-resistant IIIc/IV metastatic NSCLC treated with immune-induced radiotherapy (SBRT). Participants will be asked to accept the treatment of ICIs regimen and SBRT plan as follows: ICIs regimen: tislelizumab 200mg every 3 weeks, the first dose was given 7 days after the last SBRT treatment, then the first day of each cycle, 21 days as a cycle until disease progression. SBRT plan: The radiation dose and fractionation of SBRT should be evaluated according to the size and location of the tumor.

Conditions

• Non-Small Cell Lung Cancer Without Mutation in Epidermal Growth Factor Receptor (Disorder)

Interventions

Type	Name	Description
RADIATION	tereotactic body radiotherapy	In second-line and later treatment, the treatment regimen of SBRT combined with tislelizumab is used

Timeline

• Start date: 2024-01-01
• Primary completion: 2025-06-30
• Completion: 2025-12-31
• First posted: 2023-12-04
• Last updated: 2023-12-04